Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study

Basit Öğe Kaydı
dc.authoridSUNER, ASLI/0000-0002-6872-9901
dc.authoridCarr, Brian/0000-0002-6111-5077
dc.authorwosidSUNER, ASLI/C-1032-2012
dc.contributor.authorSuner, Asli
dc.contributor.authorCarr, Brian, I
dc.date.accessioned2024-08-04T21:00:10Z
dc.date.available2024-08-04T21:00:10Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Inflammation is a recognized concomitant of hepatocellular carcinoma (HCC) and its indices are prognostically useful. Aims: To evaluate two commonly used inflammatory indices, neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), to examine their relationship to maximum tumor diameter (MTD) and to survival. Methods: A database of 1024 prospectively-accrued HCC patients was examined, who had full baseline tumor parameter data, including CT scan information on HCC size and whose survival was known. Analyses of NLR and PLR were correlated to MDT and to survival. NLR and PLR cutoffs were calculated from receiver operator characteristic curves. Results: Every MTD pair had significantly different PLR values, for MTD groups of groups <2/>= 2, <3/>= 3, <4/>= 4, <5/>= 5 cm. However there were few significant differences in NLR values. Logistic regression models of different MTD groups likewise showed significance for PLR. Patients with both low NLR and low PLR had the longest overall survival compared to all the other 3 combinations of NLR and PLR. In a Cox regression analysis, univariate models on NLR (<= 3.02/>3.02) and PLR (<= 6.82/>6.82) groups, showed significance for PLR, p = 0.034 and approaching significance for NLR, p = 0.057. Conclusions: MTD pairs down to <2/>= 2 cm showed significance for PLR, survival showed significance for PLR and almost for NLR.en_US
dc.description.sponsorshipNIH [CA 82723]en_US
dc.description.sponsorshipThis work was supported in part by NIH grant CA 82723 [B.I.C]en_US
dc.identifier.doi10.1016/j.amsu.2020.08.042
dc.identifier.endpage171en_US
dc.identifier.issn2049-0801
dc.identifier.pmid32994979en_US
dc.identifier.startpage167en_US
dc.identifier.urihttps://doi.org/10.1016/j.amsu.2020.08.042
dc.identifier.urihttps://hdl.handle.net/11616/103863
dc.identifier.volume58en_US
dc.identifier.wosWOS:000573919500016en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofAnnals of Medicine and Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPLRen_US
dc.subjectNLRen_US
dc.subjectHCCen_US
dc.subjectSurvivalen_US
dc.titlePlatelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu